Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study.
acute lymphoblastic leukemia
blinatumomab
immunotherapy
inotuzumab ozogamicin
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
19 Sep 2023
19 Sep 2023
Historique:
received:
26
06
2023
revised:
11
09
2023
accepted:
13
09
2023
medline:
28
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
Blinatumomab (Blina) and inotuzumab ozogamicin (InO) has improved the outcome of relapsed/refractory B-lymphoblastic leukemia (R/R B-ALL). However, little is known about the outcome after recurrence and re-treatment with immunotherapy. We describe 71 R/R B-ALL patients treated for different relapses with Blina and InO. Blina was the first treatment in 57 patients and InO in 14. Twenty-seven patients had a previous allogeneic hematopoietic stem cell transplantation (allo-HSCT). In the Blina/InO group, after Blina, 36 patients (63%) achieved a complete remission (CR), with 42% of negative minimal residual disease (MRD-); after InO, a CR was achieved in 47 patients (82%, 34 MRD-). In the InO/Blina group, after InO, 13 cases (93%) reached a CR (6 MRD-); after Blina, a CR was re-achieved in 6 cases (43%, 3 MRD-). Twenty-six patients proceeded to allo-HSCT. In the Blina/InO group, the median overall survival (OS) was 19 months; the disease-free survival (DFS) after Blina was 7.4 months (11.6 vs. 2.7 months in MRD- vs. MRD+, In our series of R/R B-ALL, Blina and InO treatment demonstrate efficacy for subsequent relapses in terms of MRD response, OS and DFS, and as a bridge to allo-HSCT.
Sections du résumé
BACKGROUND
BACKGROUND
Blinatumomab (Blina) and inotuzumab ozogamicin (InO) has improved the outcome of relapsed/refractory B-lymphoblastic leukemia (R/R B-ALL). However, little is known about the outcome after recurrence and re-treatment with immunotherapy.
METHODS
METHODS
We describe 71 R/R B-ALL patients treated for different relapses with Blina and InO. Blina was the first treatment in 57 patients and InO in 14. Twenty-seven patients had a previous allogeneic hematopoietic stem cell transplantation (allo-HSCT).
RESULTS
RESULTS
In the Blina/InO group, after Blina, 36 patients (63%) achieved a complete remission (CR), with 42% of negative minimal residual disease (MRD-); after InO, a CR was achieved in 47 patients (82%, 34 MRD-). In the InO/Blina group, after InO, 13 cases (93%) reached a CR (6 MRD-); after Blina, a CR was re-achieved in 6 cases (43%, 3 MRD-). Twenty-six patients proceeded to allo-HSCT. In the Blina/InO group, the median overall survival (OS) was 19 months; the disease-free survival (DFS) after Blina was 7.4 months (11.6 vs. 2.7 months in MRD- vs. MRD+,
CONCLUSION
CONCLUSIONS
In our series of R/R B-ALL, Blina and InO treatment demonstrate efficacy for subsequent relapses in terms of MRD response, OS and DFS, and as a bridge to allo-HSCT.
Identifiants
pubmed: 37760592
pii: cancers15184623
doi: 10.3390/cancers15184623
pmc: PMC10526797
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Italian Ministry of Health - Current research IRCSS
ID : not available
Références
J Clin Oncol. 2018 Sep 21;:JCO2017773648
pubmed: 30240326
Blood Rev. 2023 May;59:101042
pubmed: 36732205
N Engl J Med. 2017 Mar 2;376(9):836-847
pubmed: 28249141
J Hematol Oncol. 2018 Mar 15;11(1):41
pubmed: 29544528
Cancer. 2021 Feb 15;127(4):554-559
pubmed: 33141929
J Clin Oncol. 2020 Feb 10;38(5):415-422
pubmed: 31815579
N Engl J Med. 2016 Aug 25;375(8):740-53
pubmed: 27292104
Haematologica. 2016 Dec;101(12):1524-1533
pubmed: 27587380
Clin Lymphoma Myeloma Leuk. 2020 Aug;20(8):556-560.e2
pubmed: 32291234
J Clin Oncol. 2017 Jun 1;35(16):1795-1802
pubmed: 28355115
Immunotherapy. 2016 Feb;8(2):135-43
pubmed: 26780449
N Engl J Med. 2018 Feb 1;378(5):449-459
pubmed: 29385376
J Hematol Oncol. 2023 Mar 16;16(1):22
pubmed: 36927623
J Hematol Oncol. 2023 May 2;16(1):44
pubmed: 37131217
N Engl J Med. 2020 Oct 22;383(17):1613-1623
pubmed: 33085860
Front Oncol. 2022 Jan 06;11:804714
pubmed: 35071008
Lancet Haematol. 2023 Jan;10(1):e24-e34
pubmed: 36402146
Lancet Haematol. 2023 Jun;10(6):e433-e444
pubmed: 37187201
Cancer. 2021 Jun 15;127(12):2025-2038
pubmed: 33740268
Cancers (Basel). 2022 Sep 20;14(19):
pubmed: 36230478
Blood Cancer J. 2020 Aug 7;10(8):81
pubmed: 32769965
Blood Adv. 2020 Apr 14;4(7):1518-1525
pubmed: 32289160
Cancer. 2021 Apr 1;127(7):1039-1048
pubmed: 33259056
Cancer Gene Ther. 2023 Jun;30(6):845-854
pubmed: 36750666
Blood. 2018 Apr 5;131(14):1522-1531
pubmed: 29358182